Journal
IN VIVO
Volume 37, Issue 1, Pages 182-189Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/invivo.13067
Keywords
oncogenic kinases; apoptosis; colorectal; Hyperforin
Categories
Ask authors/readers for more resources
This study found that hyperforin, an active constituent from Hypericum perforatum, suppresses the progression and transformation of colorectal cancer (CRC) by inhibiting the JAK/STAT3, ERK, and AKT signaling pathways, suggesting its therapeutic potential.
Background/Aim: Signal transducer and activator of signal-regulated kinase (ERK), and protein kinase B (AKT) are essential for malignant transformation and progression in colorectal cancer (CRC) and can be considered as targets for therapeutic interventions. Hyperforin, an active constituent from Hypericum perforatum, has been reported to inhibit inflammation. However, whether hyperforin may suppress CRC progression via inactivation of JAK/STAT3, ERK or AKT signaling remains unclear. Materials and Methods: Human CRC cells were used to identify the treatment efficacy of hyperforin and its underlying mechanisms of action by MTT, flow cytometry, wound healing, and western blotting assays. Results: Hyperforin not only induced cytotoxicity, extrinsic/intrinsic apoptosis signaling, but also suppressed the invasion/migration ability of CRC. The phosphorylation of STAT3, JAK1, ERK and AKT was found to be decreased by hyperforin. Conclusion: Hyperforin inactivates multiple oncogenic kinases and induces apoptosis signaling in CRC cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available